Navigation Links
NeurogesX Reports First Quarter 2009 Results
Date:5/7/2009

in proof of concept in vivo and in vitro preclinical studies for its potential to deliver therapeutic efficacy with a potential for an improved side effect profile and possible abuse-deterrent attributes.

Conference Call Details

The Company will hold its quarterly conference call today at 4:30 p.m. ET (1:30 p.m. PT) to discuss first quarter 2009 results and recent corporate updates.

To participate, please dial 1-877-407-0789 (USA) or 1-201-689-8562 (International). To access the live web cast please visit the Investor Relations section on the corporate web site at http://www.neurogesx.com.

A replay of the conference call will be available beginning May 7, 2009 at 7:30 p.m. ET (4:30 p.m. PT) and ending on May 17, 2009 by dialing 1-877-660-6853 (USA) or 1-201-612-7415 (International), Account Number: 3055, Conference ID Number: 320580. A replay of the webcast will also be available on the corporate website for one month, through June 7, 2009.

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late-stage product portfolio is led by its product candidate QutenzaTM, a dermal high-concentration capsaicin patch designed to manage pain associated with peripheral neuropathic pain conditions. NeurogesX submitted a new drug application (NDA) for Qutenza with the U.S. Food and Drug Administr
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
2. NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
3. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
4. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
5. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
6. NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference
7. NeurogesX Reports Third Quarter 2008 Results
8. NeurogesX to Report Third Quarter 2008 Financial Results
9. NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
10. NeurogesX Responds to EMEAs Day 120 Questions
11. NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... NY (PRWEB) , ... July 03, 2015 , ... Cuvettes have been used in countless ... style catalog to find the cuvette they needed. As expected, this was a daunting ... order the wrong part because they were not able to navigate the complex catalog structure. ...
(Date:7/2/2015)... ... 02, 2015 , ... In’Tech Medical SAS ( http://www.intech-medical.com ), ... today the acquisition of Turner Medical, Inc ., thus becoming a global ... the Spine Industry. The acquisition of Turner Medical ideally supplements In’Tech Medical’s product ...
(Date:7/1/2015)... AURORA, Colo. and BANGALORE, India ... a global genomic profiling company that uses next generation ... appointment of Scott A. Storrer as chief ... and CEO, he will be responsible for all strategy, ... Vijay Chandru , who has served as Strand,s chairman ...
(Date:7/1/2015)... InferMed , s ... will augment Elsevier ... olutions suite   Elsevier , a world-leading ... announced today the acquisition of  InferMed , a ... InferMed,s Arezzo technology supports clinicians in choosing the most ...
Breaking Biology Technology:New Cuvette E-Commerce Website Launched by FireflySci 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4
... are the words of the automated announcement that one used ... whenever the doors opened. The gap refers to the space ... through the American workplace today, I cant help thinking that ... the country. In this case, the gap to watch out ...
... The Milwaukee Brewers will soon have ... players at Miller Park, officials announced Thursday. , ,Eastman ... will provide a Directview CR 850 computer-operated ... will be used to generate high-resolution digital X-rays of ...
... award from Raj Veeramani, director of the E-Business Institute. ... is a brave new world of advertising, says Jerry Shereshewsky, ... University of Wisconsin student (and cohort of former Madison Mayor ... his impact on the future of business. He was a ...
Cached Biology Technology:Minding the Generation Gap 2Minding the Generation Gap 3Advertising ambassador explains the reinvention of marketing 2Advertising ambassador explains the reinvention of marketing 3
(Date:6/29/2015)... June 24, 2015 Research ... the "Latin America Biomedical Sensors Market - Growth, ... The Latin America Biomedical Sensors market is ... of 2.04% over the period 2014-2020 The ... to the genetic formulation of each individual. These sensors ...
(Date:6/24/2015)... , June 24, 2015 The biologics ... The major drivers for the market include growth of ... of new drug launches. Over the years, the number ... Between 2001 and 2010, the FDA approved 225 drug ... to WIPO, Europe accounted for ...
(Date:6/23/2015)... , June 23, 2015   MedNet Solutions ... supports the entire spectrum of clinical research, is ... ™ , the company,s intuitive, flexible and ... a Silver 2015 Stevie® Award by the ... & Services Website category.  The American Business Awards ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2
... Vision Australia (BVA) today unveils their wide-view neurostimulator concept ... Australia,s first recipient of the technology. The ... University of New South Wales and unveiled today at ... Melbourne, will deliver improved quality of life for patients ...
... helping fight a multi-front war on cancer may do the ... Cancer and cardiovascular disease, both among top U.S. killers, ... as a treatment could become additional common ground, said Dr. ... think hsp90 inhibitors may be some of the best anti-inflammatory ...
... March 30, 2010 Two new tuberculosis studies by ... bad news about the bacterium that infects nearly a ... kills nearly 2 million people each year. ... shows promise at overcoming some drug-resistant tuberculosis, at least ...
Cached Biology News:Bionic Vision Australia puts bionic eye in sight 2New cancer therapy may fight cardiovascular disease 2UT Southwestern researchers find clues to TB drug resistance 2UT Southwestern researchers find clues to TB drug resistance 3
Chicken polyclonal to HADHSC - Azide free ( Abpromise for all tested applications). Antigen: Amino acids 57-314 of HADHSC Entrez GeneID: 3033 Swiss Protein ID: Q16836...
Rabbit polyclonal to ZNF261 ( Abpromise for all tested applications). entrezGeneID: 9203 SwissProtID: Q14202...
...
Mouse monoclonal [ICRF 44] to Integrin alpha M...
Biology Products: